Can a Four-Drug cocktail tame a tough breast cancer?
NCT ID NCT03304080
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial is testing whether combining four drugs—anastrozole, palbociclib, trastuzumab, and pertuzumab—can safely and effectively treat HR-positive, HER2-positive metastatic breast cancer as a first-line therapy. The study involves people who have not received prior systemic treatment for metastatic disease. Researchers are evaluating the safety of the combination, the best dose of palbociclib, and how well the treatment controls the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of anastrozole, palbociclib, trastuzumab, and pertuzumab
- What this could lead to
- If successful, this combination could offer a new first-line treatment option that targets both hormone receptors and HER2, potentially improving outcomes for people with this type of metastatic breast cancer.
- What could go wrong
- This is an early-phase trial, so safety and the best dose are still being determined. Side effects from combining multiple drugs could be significant, and the approach may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mount Sinai Beth Israel Comprehensive Cancer Center West
New York, New York, 10011, United States
-
Mount Sinai West
New York, New York, 10019, United States
-
New York Presbyterian Columbia Irving Comprehensive Cancer Center
New York, New York, 10032, United States
-
New York Presbyterian Weill Cornell Medical Center
New York, New York, 10065, United States
-
Perlmutter Cancer Center NYU Langone
New York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smartwatch could spot nerve damage before it starts
- Can acupuncture soothe the mind and body in breast cancer?
- CT scans may predict breast reconstruction flap failure
- A gentle jog might be the key to better sleep for breast cancer survivors
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?